ACHVHealthcare · Biotechnology

ACHV Stock Forecast: Achieve Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$8.00

−0.25% on the day

The 11 Wall Street analysts covering Achieve Life Sciences, Inc. hold a median 12-month price target of $13 — +56.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$822.2M

Ticker Nerd rank

29 / 100

Median analyst target

$13

Analysts covering

Total return, dividends reinvested

+5.4%

+23.1%

YTD

+61.0%

+176.8%

From 52W high

−6.2%

From 52W low

+201.9%

$2.65

$8.53

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

ACHV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Achieve Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum

Accruals

Size

Growth

Value

Revisions

Volatility

Quality

Issuance

Momentum (97): The shares have been drifting up relative to others.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACHV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACHV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts

11 Buy0 Hold0 Sell

Low $9Median $13High $21

The green dot is the last close — the median target sits +56.3% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
13 Aug 2026	Morgan Stanley	Initiates	Overweight	$13
22 June 2026	HC Wainwright & Co.	Reiterates	Buy	$12
22 June 2026	HC Wainwright & Co.	Reiterates	Buy	—
21 Apr 2026	Canaccord Genuity	Initiates	Buy	—
16 Apr 2026	HC Wainwright & Co.	Reiterates	Buy	—
25 Mar 2026	HC Wainwright & Co.	Reiterates	Buy	—
25 Nov 2025	Citizens	Initiates	Market Outperform	—
21 Aug 2025	HC Wainwright & Co.	Initiates	Buy	—
14 Nov 2024	Rodman & Renshaw	Initiates	Buy	—
27 Sept 2024	Raymond James	Initiates	Strong Buy	$20
15 Aug 2024	Oppenheimer	Reiterates	Outperform	—
13 May 2024	Oppenheimer	Maintains	Outperform	—
17 Apr 2024	JonesTrading	Initiates	Buy	—
1 Apr 2024	Oppenheimer	Reiterates	Outperform	—
5 Mar 2024	Lake Street	Maintains	Buy	—
12 Dec 2023	Oppenheimer	Maintains	Outperform	—
1 June 2023	Lake Street	Maintains	Buy	—
31 May 2023	Lake Street	Maintains	Buy	—
10 May 2023	Lake Street	Maintains	Buy	—
17 Mar 2023	Oppenheimer	Reiterates	Outperform	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACHV appears on the weeks it earns a place.

Estimates

ACHV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Achieve Life Sciences, Inc. (ACHV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −6.4×
Price / sales: —
Price / book: 39.9×
EV / EBITDA: −11.2×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −845.0%
Return on assets: −29.2%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ACHV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
ACHVAchieve Life Sciences, Inc.	$822.2M	29
FTHFaeth Therapeutics, Inc.	$824.9M	54
AURAAura Biosciences, Inc.	$806.4M	41
RIGLRigel Pharmaceuticals, Inc.	$849.1M	79
TBPHTheravance Biopharma, Inc.	$856.6M	89
GYREGyre Therapeutics, Inc.	$770.4M	39
FDMT4D Molecular Therapeutics, Inc.	$874.5M	53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Achieve Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACHV news & analysis

Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality

GlobeNewsWire · 3 Aug 2026positive

Achieve Life Sciences has appointed Ronald Dadino as Senior Vice President of CMC and Supply Chain, and Gloria Cosgrove as Senior Vice President of Quality, both bringing decades of pharmaceutical leadership experience.

Why it matters — Strengthening CMC, supply chain, and quality leadership signals that Achieve is building the operational infrastructure needed to support the potential commercialization of cytisinicline.

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

GlobeNewsWire · 31 July 2026neutral

Achieve Life Sciences announced that its board of directors approved stock option grants for 1,190,000 shares and restricted stock unit awards for 125,000 shares to six new employees under the company's 2024 Equity Inducement Plan.

Why it matters — The inducement awards signal the company is hiring and incentivizing new talent, which may be relevant as it progresses development of cytisinicline for nicotine dependence.

FAQ

Frequently asked questions about ACHV stock

What is the ACHV stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Achieve Life Sciences, Inc. have a median 12-month price target of $13, with estimates ranging from $9 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACHV stock a buy right now?

Of the 11 analysts covering Achieve Life Sciences, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Achieve Life Sciences, Inc. 29 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACHV?

As at 22 Aug 2026, Achieve Life Sciences, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will ACHV stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +56.3% from the last close, and Ticker Nerd's factor model ranks Achieve Life Sciences, Inc. 29 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACHV stock forecast for 2030?

No analyst covering Achieve Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACHV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $21 over the next 12 months.

How has ACHV stock performed over the past year?

Achieve Life Sciences, Inc. returned +176.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Achieve Life Sciences, Inc. do?

What is the latest news on ACHV?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality". Achieve Life Sciences has appointed Ronald Dadino as Senior Vice President of CMC and Supply Chain, and Gloria Cosgrove as Senior Vice President of Quality, both bringing decades of pharmaceutical leadership experience.

Company

About Achieve Life Sciences, Inc.

Achieve Life Sciences Inc. is a late-stage specialty pharmaceutical company dedicated to combating the global smoking health epidemic and nicotine addiction through the development and commercialization of cytisinicline. Cytisinicline is a plant-based alkaloid that binds to nicotinic acetylcholine receptors in the brain, helping to reduce nicotine withdrawal symptoms and cravings, positioning it as a potential treatment for smoking cessation and nicotine dependence, including e-cigarette and vaping cessation. The company operates within the biotechnology sector of healthcare, focusing on innovative therapies to address nicotine addiction, a leading cause of preventable death worldwide. Achieve Life Sciences Inc. pursues regulatory approvals and partnerships for manufacturing to support commercialization efforts in key markets. Headquartered in Bothell, Washington, United States, the company emphasizes advancing cytisinicline as a widely available treatment option for individuals seeking to quit nicotine products.

CEO Dr. Andrew D. Goldberg M.D. · 28 employees · United States · https://www.achievelifesciences.com